Updated:
The Lachesis Fund
The Lachesis Fund gets first look at IP from eight Midlands universities. Mark White has managed this early-stage vehicle since 2001.
The Lachesis Fund
The Lachesis Fund launched in 2001 as a proof-of-concept and seed-stage vehicle tied to Loughborough University. Eight Midlands universities — Loughborough, Leicester, De Montfort, Nottingham, Nottingham Trent, Derby, Lincoln, and Northampton — eventually joined as partners, each feeding early-stage intellectual property into the fund's pipeline. This consortium structure means Lachesis sources from over 15,000 academic researchers, a density no standalone Midlands seed fund matches. The fund writes initial cheques of £50,000–£250,000 into university spin-outs, typically as the first institutional money after grant funding. Deal flow concentrates in engineering, healthcare technologies, advanced materials, and sustainability. Confirmed portfolio companies include Intelligent Energy, the Loughborough fuel-cell developer that later listed on the London Stock Exchange; Nemaura Pharma, a transdermal drug delivery company that went public on Nasdaq; and Base4, a biotech automation platform. Lachesis often syndicates with the university venture arms of Oxford and Cambridge on follow-on rounds, though it leads pricing at the seed stage for Midlands-founded companies. Total deployment since inception approaches £12 million across roughly 45 companies (Altss estimate). The fund operates with a lean in-house team — typically one fund manager and an investment committee drawn from partner universities' commercialisation offices. In 2023, the UK government renewed its backing of university proof-of-concept funds through Research England, indirectly validating the model Lachesis has run for two decades (per UKRI, 2023). The fund's structural differentiator is its geography-as-franchise model. Lachesis does not compete for auctioned deals in London or Cambridge; it holds formal right-of-first-review agreements with its eight partner institutions. For an allocator mapping UK deep-tech origination outside the Golden Triangle, Lachesis is the institutional bottleneck on Midlands academic deal flow.
General information
Firm type
Private Equity
Year founded
2001
AUM
GBP 5M — 25M (Altss estimate)
Location
Region
Europe
Country
United Kingdom
City
Loughborough
Corporate office
Loughborough, Leicestershire, United Kingdom
Principals
Mark White
Fund Manager
Sector focus
Frequently asked questions
How does The Lachesis Fund source proprietary deal flow?
Lachesis operates under formal partnerships with eight Midlands universities — Loughborough, Leicester, De Montfort, Nottingham, Nottingham Trent, Derby, Lincoln, and Northampton. Through these agreements, it receives early referral rights on commercialisable research emerging from over 15,000 academics. This consortium model gives the fund a sourcing pipeline that is structurally closed to outside venture investors until Lachesis has evaluated the opportunity.
What is the fund's relationship to its university partners?
Lachesis is an independent fund, not a university treasury vehicle. Partner universities contribute commercialisation office support and deal flow; the fund itself makes independent investment decisions. This separates academic governance from investment governance, allowing Lachesis to negotiate terms at arms' length from the originating institution while still enjoying privileged access to their research pipelines.
What cheque sizes does Lachesis write?
Initial investments typically range from £50,000 to £250,000, positioning Lachesis at the proof-of-concept and seed stages. These cheques are often the first institutional capital a spin-out receives, bridging the gap between research grants and larger Series A rounds. The fund will occasionally participate pro-rata in follow-on rounds when syndicating with later-stage co-investors.
Which sectors does The Lachesis Fund focus on?
The deal flow mirrors the research strengths of its partner universities. Core areas include advanced engineering, healthcare technologies, materials science, clean energy, and agri-tech. Intelligent Energy (fuel cells), Nemaura Pharma (drug delivery), and Base4 (biotech automation) are among the companies that emerged from this pipeline.
Does Lachesis co-invest alongside other venture investors?
Yes — Lachesis often syndicates follow-on rounds with other UK university-anchored seed funds, including those linked to Oxford and Cambridge. The fund typically leads pricing at the initial seed stage for Midlands-originated companies, then invites co-investors into subsequent rounds once the technology has been de-risked.
How long has the fund been operating, and what is its track record?
The Lachesis Fund launched in 2001, making it one of the longest-running university-anchored seed vehicles in the UK. Across more than two decades, it has deployed approximately £12 million into roughly 45 companies (Altss estimate). Notable exits and public listings include Intelligent Energy (LSE) and Nemaura Pharma (Nasdaq), though the portfolio remains predominantly early-stage and illiquid.
Is Lachesis raising a new fund, and can external LPs invest?
Historically, Lachesis has been capitalised through grants from UK government bodies such as the Higher Education Innovation Fund and Research England, alongside partner university commitments. The fund does not publicly market to external limited partners, and its current fundraising status is not disclosed. Allocators interested in exposure would need to inquire directly about LP participation terms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: